Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Don't stress about it!: Is stress management a disease-modifying therapy for multiple sclerosis?
The Submaximal Clinical Exercise Tolerance Test (SXTT) to Establish Safe Exercise Prescription Parameters for Patients with Chronic Disease and Disability.
DemTect, PANDA, EASY, and MUSIC: Cognitive Screening Tools with Age Correction and Weighting of Subtests According to Their Sensitivity and Specificity.
Do positive or negative stressful events predict the development of new brain lesions in people with multiple sclerosis?
Incidental MRI anomalies suggestive of multiple sclerosis: the radiologically isolated syndrome.
Identifying autoantigens in demyelinating diseases: valuable clues to diagnosis and treatment?
Medical marijuana: clearing away the smoke.
Direct demonstration of elevated aldehyde dehydrogenase in human hematopoietic progenitor cells.
The AusD Study: A Population-based Study of the Determinants of Serum 25-Hydroxyvitamin D Concentration Across a Broad Latitude Range.
Modulation of Sox10, HIF-1α, Survivin, and YAP by Minocycline in the Treatment of Neurodevelopmental Handicaps following Hypoxic Insult.
Genmab collaborator GSK starts new ofatumumab Phase III study in rare skin disorder
Central motor conduction time may predict response to fampridine in patients with multiple sclerosis.
MRI in multiple sclerosis: a review of the current literature.
Association between Change in Normal Appearing White Matter Metabolites and Intrathecal Inflammation in Natalizumab-Treated Multiple Sclerosis.
The environment and disease: association or causation?
Accelerated and enhanced effect of CCR5-transduced bone marrow neural stem cells on autoimmune encephalomyelitis.
In vivo evidence of glutamate toxicity in multiple sclerosis.
Estimation of the effect of dalfampridine on health utility by mapping the MSWS-12 to the EQ-5D in multiple sclerosis patients.
HERV-W envelope protein inhibits oligodendroglial precursor cell differentiation.
Targeting insulin-like growth factor 1 leads to amelioration of inflammatory demyelinating disease.
Teva and Takeda announce agreement for glatiramer acetate for multiple sclerosis treatment in Japan
Varicella-zoster virus acute myelitis in a patient with MS treated with natalizumab.
Molecular targets of FTY720 (fingolimod).
Novartis receives European Commission approval for Gilenya®, the first oral multiple sclerosis treatment for use in the EU
Energy Cost of Walking and Its Association With Gait Parameters, Daily Activity, and Fatigue in Persons With Mild Multiple Sclerosis.

Pages